Detecting Workflow Drift before Pharmacy Algorithms Learn the Wrong Practice

INTRODUCTION

Clinical algorithms are commonly developed under assumptions about how data are generated, which patients enter a pathway, who records decisions, and how outcomes become observable. These assumptions may weaken when clinical environments, professional practices, technologies, or data-generating processes change after development [1]. In pharmacy, the resulting problem is not limited to declining discrimination or calibration. An algorithm may remain statistically stable while the work surrounding it changes sufficiently to alter the meaning of its inputs, overrides, labels, and feedback.

Clinical value therefore depends on more than model accuracy. It also depends on integration into medication-use pathways, alignment with professional work, and evaluation under the conditions in which an output is interpreted and acted upon [2]. A prediction delivered to a pharmacist before verification is not functionally equivalent to the same prediction delivered after dispensing, to another professional group, or through a documentation field introduced for administrative rather than clinical purposes.

Responsible health-machine-learning deployment consequently requires lifecycle monitoring, stakeholder oversight, and safeguards against harm [3]. However, conventional monitoring often privileges model-level indicators while treating workflow as a relatively stable deployment environment. This assumption is especially problematic for systems that learn from subsequent clinician actions, accepted recommendations, override patterns, or routinely documented outcomes. Such systems can absorb not only improved practice but also staffing-related shortcuts, alert avoidance, delayed documentation, role substitution, or temporary crisis procedures.

Machine-learning systems can produce unintended clinical and sociotechnical consequences even when their technical objectives appear to have been achieved [4]. In a pharmacy context, an algorithm may optimize conformity with observed behavior while that behavior is becoming less safe, less equitable, or less consistent with intended professional standards. “Learning from practice” is therefore not necessarily equivalent to learning correct practice.

Artificial-intelligence applications are expanding across pharmacy operations and professional activities, although evidence concerning patient-centered and practice consequences remains less mature than evidence concerning operational applications [5]. This article addresses that gap by proposing a governance framework for detecting and managing workflow drift before changed practice is incorporated into algorithmic learning. The contribution is conceptual rather than empirical: it defines a pharmacy-specific construct, specifies observable dimensions and relationships, separates detection from diagnosis, and proposes constraints on when changed workflow data may inform continued learning.

Defining Workflow Drift in Pharmacy

Concept drift traditionally concerns temporal change in relationships relevant to prediction and should be distinguished from a simple change in the distribution of observed variables [6]. Data drift may alter what the model receives, whereas concept drift may alter how those variables relate to a target. Performance drift describes a measured change in model behavior. None of these concepts, alone, identifies whether the work producing the data has changed.

Process-oriented literature shows that drift may involve control flow, data, resources, roles, and temporal behavior [7]. This broader perspective is important for pharmacy because medication-related work is distributed across people, technologies, organizational units, and time. A changed process may affect which actions occur, who performs them, their order, the cases exposed to them, and how actions are represented in digital records.

Healthcare process mining can reveal actual pathways, repeated deviations, and temporal patterns, but event logs remain partial representations of clinical work [8]. Informal consultation, tacit reasoning, interruptions, verbal clarification, and undocumented workarounds may be absent. An observed change in a digital trace may therefore reflect a real workflow change, a documentation change, or a technical extraction problem.

Drift analysis must also proceed beyond alarm generation toward identifying what changed, where it changed, and when the change occurred [9]. A monitoring signal is not a diagnosis. Abrupt changes may follow software releases or policy changes; gradual changes may reflect learning, workload adaptation, or normalization of workarounds; cyclical changes may reflect staffing or seasonal patient patterns. Each requires different investigation.

This article therefore proposes that pharmacy workflow drift is a material change over time in the tasks, professional roles, activity sequence, patient or case population, or documentation practices through which medication-related work is produced and represented, where that change can alter algorithm inputs, labels, feedback, use conditions, or consequences. The definition is sociotechnical because medication safety emerges from interactions among people, tasks, technologies, organizational conditions, and care environments [10]. Workflow drift differs from expected variation within an accepted process and from deliberately governed redesign. It also does not presume deterioration: some drift may represent improvement. The governance concern arises when a material change is unrecognized, insufficiently understood, or incorporated into learning without determining whether it reflects acceptable practice.

Table 1 organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for definitions, components, relationships, and intended uses for the article Detecting Workflow Drift before Pharmacy Algorithms Learn the Wrong Practice.

The table’s dimensions are proposed organizing constructs rather than validated diagnostic categories. Their observability, separability, and usefulness require empirical testing in different pharmacy settings.

Proposed Multidimensional Drift Framework

Figure 1 presents the original conceptual synthesis for multidimensional pharmacy workflow-drift framework, showing how the article’s principal components, evidence relationships, uncertainties, and decision boundaries are connected.

The framework places a pharmacy work system–algorithm learning interface at its center. This reflects the human-factors principle that work-system conditions, care processes, outcomes, transitions, and feedback should be considered together rather than as isolated technical elements [11]. The central interface is surrounded by a baseline workflow contract, five drift dimensions, an observability layer, a consequence layer, and a learning-control layer.

The baseline workflow contract is a proposed, versioned description of the algorithm’s intended task, authorized users, patient population, expected sequence, documentation sources, feedback pathway, autonomy level, and escalation conditions. It is not a legal contract. Its purpose is to make assumptions about work explicit enough to compare intended and observed practice.

The five-dimensional observability layer assesses task, role, sequence, population, and documentation change. Human–AI performance depends on complementarity and appropriate division of work rather than the substitution of an isolated algorithm for professional judgment [12]. Role drift is therefore not merely a change in username or staffing category; it may alter who interprets an output, who possesses authority to act, and who creates the feedback later treated as ground truth.

The consequence layer separates model performance from clinical task performance, workflow consequence, medication safety, patient experience, equity, implementation burden, and accountability. This separation is important because medication-alert optimization remains limited by incomplete external validation and routine implementation evidence [13]. A model can produce technically improved prioritization without establishing that the resulting work is safer, more equitable, or professionally usable.

The learning-control layer governs whether changed data may influence future behavior. Alert effects can depend on interaction design and the clinical role receiving the alert [14]. Consequently, an apparent improvement in acceptance or override rates may reflect changed placement, responsibility, or workload rather than improved clinical appropriateness. The proposed framework treats such changes as diagnostic questions rather than direct learning targets.

Conceptual layout: Baseline workflow assumptions feed the central work system–algorithm interface. Five surrounding drift dimensions supply candidate signals. Signals enter a consequence-assessment boundary before reaching the learning-control layer. Feedback arrows from algorithm outputs to professional actions and subsequent documentation indicate that the system can reshape the data from which it later learns. Dashed cross-links indicate proposed,

Table 2 organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for evaluation criteria, evidence requirements, and failure modes for the article Detecting Workflow Drift before Pharmacy Algorithms Learn the Wrong Practice.

The framework does not rank the five dimensions or assume that all must be monitored with equal intensity. Monitoring scope should be conditional on the algorithm’s task, autonomy, feedback pathway, medication-safety consequences, and the organization’s capacity to investigate signals.

Detecting Task, Role, Sequence, Population, and Documentation Drift

Detection should combine statistical, process, organizational, and qualitative evidence. Empirical drift-detection studies show that performance depends on feature selection, sample characteristics, and the detection method used [15]. A pharmacy organization should therefore validate candidate signals locally rather than import thresholds from another technology or setting. Detection should also complement, not replace, monitoring of clinical and operational consequences.

Task drift may be reflected in changed intervention categories, new verification steps, altered exception handling, task substitution, or a shift from clinical assessment toward administrative completion. Role drift may appear when actions move among pharmacists, technicians, physicians, nurses, automated services, or supervisory levels. Relevant indicators include role-resolved event logs, authorization records, assignment patterns, escalation routes, and qualitative reports from staff. These indicators remain incomplete when actual authority differs from the identity recorded in the system.

Sequence drift concerns changes in order, timing, handoffs, parallel work, or bypassed stages. Time-stamped medication orders, verification events, dispensing records, interventions, acknowledgements, and overrides may reveal altered pathways. However, delayed or retrospective documentation can create a digital sequence that differs from the sequence of actual care.

Population drift concerns changes in the patients or cases entering an algorithm-supported pathway. Candidate indicators include care setting, age, morbidity, medication complexity, language, service eligibility, referral source, and formulary exposure. Population change may alter workload and model inputs without constituting workflow drift. It becomes workflow-relevant when it changes which tasks are performed, how responsibilities are distributed, or whether existing processes remain appropriate.

Documentation drift requires particular caution because EHR data quality is multidimensional and dependent on fitness for the intended use [16]. Changes in missingness, template adoption, code substitution, copy-forward, free-text practices, delayed entry, or source-system linkage can alter the apparent prevalence of clinical actions without equivalent changes in practice. Monitoring should therefore compare data sources, documentation timing, and extraction pipelines before interpreting record-level changes as clinical change.

Workflow fragmentation and documentation burden can also redistribute where, when, and by whom information is recorded [17]. A new documentation field may improve traceability, create duplicate work, or shift recording to a person who did not make the underlying decision. Conversely, disappearance of a coded intervention may reflect migration to free text rather than cessation of the intervention. Documentation signals should therefore be investigated alongside staffing, workload, policy, interface, and observational evidence.

Contextual analysis of clinical decision support can reveal whether an apparent problem is associated with workflow configuration, staffing, education, or system design rather than the predictive model itself [18]. Explainability methods may assist localization, but they do not establish causation. The proposed detection process consequently treats every signal as one of four preliminary possibilities: genuine workflow drift, expected variation, documentation or technical artifact, or unresolved change. Only structured diagnosis can determine whether the algorithm’s learning state should change.

Diagnosis, Response, and Learning Constraints

A detected signal should initiate diagnosis rather than adaptation. The causal source of a distributional change should be examined before selecting an update because associations learned under one data-generating process may not remain valid after that process changes [19]. Diagnosis should ask what changed, when and where it changed, whether the change was planned, and how it affected algorithm inputs, outputs, labels, overrides, or observed outcomes.

Continual monitoring should connect detection to investigation, controlled updating, and quality-improvement governance [20]. The proposed pathway is signal → triage → localization → contextual diagnosis → consequence assessment → containment → learning-state decision. Relevant explanations include service redesign, staffing pressure, shortages, policy or formulary changes, interface modification, extraction failure, documentation migration, population change, and emergent workaround.

Maintenance also requires user reporting, disablement, rollback, and retirement pathways rather than metric surveillance alone [21]. The proposed learning states are continued operation, enhanced surveillance, learning freeze, restricted inference, controlled update and revalidation, rollback, or retirement. Adaptive clinical decision support requires transparent oversight and controlled change [22]. Accordingly, no drift signal should directly authorize learning; labels created during unresolved high-consequence disruption should be quarantined where feasible; target redefinition should be explicit; and resumption of learning should require accountable authorization.

These states and constraints are proposed. Their thresholds, comparative effects, workload, and medication-safety consequences require local empirical validation.

Drift-Evaluation and Governance Requirements

Evaluation must distinguish detection performance from usefulness in live medication-related work. Early clinical evaluation of AI decision support should examine workflow integration, human factors, errors, and failures rather than model performance alone [23]. The framework therefore requires assessment of signal validity, temporal sensitivity, false-alarm burden, localization, professional usability, clinical task performance, medication safety, subgroup stability, and rollback reliability.

Trustworthy healthcare AI evaluation also encompasses fairness, universality, traceability, usability, robustness, and explainability across the lifecycle [24]. Bias assessment should examine data, modeling, implementation, and subgroup consequences rather than relying on one aggregate fairness measure [25]. Continual-learning systems additionally require predefined change-control and monitoring boundaries [26].

The proposed transition gates are: signal validity, localization, causal plausibility, consequence, evidence sufficiency, accountable authorization, and postchange requalification. Passing these gates would document a reasoned decision; it would not independently establish effectiveness, regulatory compliance, or unrestricted deployment readiness.

Implementation Implications

Implementation should anticipate complexity, nonadoption, abandonment, scale-up, and sustainability rather than treating technical installation as completion [27]. Context assessment should consider the intervention, inner and outer settings, involved individuals, and implementation process [28]. Workflow fit, trust, training, technical integration, and organizational resources may facilitate or obstruct routine AI use [29]. Operational deployment also requires explicit infrastructure for triggering, data flow, feedback, monitoring, evaluation, and controlled release [30].

Table 3 organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for governance responsibilities, implementation conditions, and monitoring requirements for the article Detecting Workflow Drift before Pharmacy Algorithms Learn the Wrong Practice.

Figure 2 presents the original conceptual synthesis for drift detection, diagnosis, response, and learning constraints, showing how the article’s principal components, evidence relationships, uncertainties, and decision boundaries are connected.